Eco Animal Health Gp - Notice of Results

ECO Animal Health

20/11/2025 07:00

RNS Number : 3635I

Eco Animal Health Group PLC

20 November 2025

 

The following amendment has been made to the 'Notice of Results' announcement released on 20 November 2025 at 07.00am under RNS No 2684I.

 

The results period has been corrected to the six months ended 30 September 2025.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

 

20 November 2025

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Notice of Results

Analyst Briefing and Investor Presentation

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, will announce its unaudited interim results for the six months ended 30 September 2025 on 1 December 2025.

 

David Hallas, CEO, and Christopher Wilks, CFO, will host an in-person analyst briefing at 09:00 GMT on 1 December 2025. There will be a dial-in option for those unable to attend in person. For further information about the analyst presentation, please contact ecoanimalhealth@icrhealthcare.com.

 

In addition, David Hallas and Christopher Wilks will conduct a live online presentation and Q&A at 14:00 GMT on 2 December 2025.  This event is open to all existing and potential shareholders and registration is free. To register for the event, please click here.

 

 

-Ends-

 

Contacts

ECO Animal Health Group plc
David Hallas (Chief Executive Officer)
Christopher Wilks (Chief Financial Officer)
020 8447 8899
ICR Healthcare (Financial PR)
Mary-Jane Elliott
Jessica Hodgson
020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker)
Philip Davies
Sam Butcher
020 7496 3000
Panmure Liberum (Joint Broker)
Emma Earl
Will Goode
Mark Rogers
Rupert Dearden
020 3100 2000
Equity Development
Hannah Crowe
Matt Evans
020 7065 2692

 



About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

 

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

 

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

 

Click here for more information: https://ecoanimalhealth.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NORBMBLTMTITMIA